blog

As the year comes to an end, we reflect with gratitude on the trust and connection we share with all who inspire and support our work. At biosyn Arzneimittel GmbH, our dedication to improving lives through innovative research and compassionate care remains at the core of everything we do. This festive...

Continue reading

biosyn Arzneimittel GmbH announces Pascal Voltzenlugel as Managing Director/CEO - ensuring positive development. Fellbach, November 1st 2023 - At the shareholders' meeting of biosyn Arzneimittel GmbH, Pascal Voltzenlugel was appointed as the new Managing Director and CEO of the company. This key decision marks a significant milestone for biosyn and is...

Continue reading

The shareholders' meeting of biosyn appointed Pascal Voltzenlugel as Managing Director/CEO of biosyn Arzneimittel GmbH. The Managing Director represents the company exclusively. Pascal Voltzenlugel is a pharmacist, a graduate of the University of Strasbourg and holds an MBA (Master of Business Administration) from Noema Business Scholl. He has outstanding knowledge in...

Continue reading

WOCOIO - WORLD CONGRESS OF INTEGRATIVE ONCOLOGY WOCOIO offers the most recent therapeutic developments in Integrative Oncology and networking with the world’s top physicians in this field! biosyn Arzneimittel GmbH invites you to attend the first version of WOCOIO! For registration, please click here:  World Congress Of Integrative Oncology Organized by ESIO: www.esio.info More info: www.wocoio.com  

Continue reading

Since 2014, the Stifterverband has recognized research-based companies for the special responsibility they assume for the state and society with the "Innovative through Research" seal. biosyn Arzneimittel GmbH has been awarded the seal for the years 2020 and 2021. Thomas Stiefel, biosyn co-founder and managing director, is pleased about this. "The...

Continue reading

In Germany, around 1.7 million people have Alzheimer's disease or another dementia disorder. This is a term used to describe various conditions in which mental performance declines quite sharply over time. By far the majority of those affected have Alzheimer's. More than 300,000 new cases occur every year. There is no...

Continue reading

biosyn Arzneimittel GmbH (selenase, calcivitase, zincotase), a company specializing in trace elements, is active in many parts of the world. Currently, there are approvals for the company's products in 27 countries. The company specifically focuses on internationalization. Opportunities in new markets are regularly reviewed. biosyn is a leader in selenium products....

Continue reading

biosyn Arzneimittel GmbH is launching two new dietary supplements in Germany - myflora comfort and myfemella. Both products contain sporebiotics and botanicals. Most classic bacterial cultures, such as lactobacilli or bifidobacteria, do not survive the acidic environment of the stomach. To make them more resistant, they are often chemically coated. Nevertheless,...

Continue reading

biosyn Arzneimittel GmbH is a leader in high-dose selenium injections. Now the medium-sized family-owned company has received approval for France for a selenase injection preparation. Managing partner Thomas Stiefel is particularly pleased about this positive decision. "We have convinced the French authorities of the quality of our products." He points out...

Continue reading

biosyn Arzneimittel GmbH is a leader in selenium products. Now the medium-sized family-owned company is represented in Georgia with selenase. Another step in the internationalization strategy of the hidden champion. Managing partner Ortwin Kottwitz emphasizes the importance of foreign markets. "We regularly examine opportunities in new markets and are pleased when...

Continue reading